Home > Boards > US OTC > Medical - Equipment >

Curative Biotechnology Inc. (CUBT)

CUBT RSS Feed
Add CUBT Price Alert      Hide Sticky   Hide Intro
Moderator: i_like_bb_stock, Eagle1, Threeflight, pepeoil, trader59, Giffy
Search This Board: 
Last Post: 5/18/2022 8:29:24 PM - Followers: 315 - Board type: Free - Posts Today: 0

 
OTC: CUBT

http://CurativeBiotech.com

INVESTOR PRESENTATION

https://curativebiotech.com/news-and-media/presentations

Curative Biotechnology, a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop an adjuvant for the COVID-19 vaccines which enhance antibody response.

Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com

Current Drug Pipeline  https://curativebiotech.com/pipeline

Treatments for six (6) Ocular conditions, one (1) Oncology, one (1) Infectious disease and one (1) vaccine adjunct candidate 

* Metformin eyedrops for treatment of Acute Macular Degeneration (AMD)
* Treatments for Stargardt's disease, Retinitis Pigementosa, Choroidereia, Diabetic Retinopathy and Late Onset Retinal Degeneration

* Treatment for Pediatric Brain Cancer(Gioblastoma)
*  Treatment for Symptomatic Rabies with potential for a Priority Review Voucher (PRV) with monteziation opportunity of over $100 Million
*  Development of a next generation COVID-19 vaccine for kidney failure patient population (immuno-compromised). Enhanced antibody titer levels rcorded when used as an adjunct with current vaccines
 


NATIONAL EYE INSITUTE STRATEGIC PLAN--Vision for the Future

https://www.nei.nih.gov/sites/default/files/2021-12/NEI-StrategicPlan-VisionForTheFuture_508_edit.pdf

Age-Related Macular Degeneration (AMD)

AMD is a visually threatening condition, most often found in patients over age 60. Early and Intermediate AMD are characterized by enlarged drusen behind the eye’s retina. Close to 10% of the world’s population is over 60, increasing the prevalence of age-related macular degeneration. Dry AMD accounts for 80-90% of AMD cases, while wet AMD is 10-20% of cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late stage dry AMD). Wet AMD is caused by blood vessels that leak in the retina. These abnormal blood vessels may leak fluids or blood into the back of the eye.

Curative Biotech will reformulate metformin to treat intermediate dry AMD and Geographic Atrophy for the first indications. Development to be led by the lead inventor on the NEI Patents, Dr. Kapil Bharti. Curative is in negotiations with NEI to conduct the first clinical trial. This product may be eligible for 505(b)(2) treatment as a reformulation of an already approved drug.

The global age-related macular degeneration (AMD) market is expected to attain a value of $8.9 billion by 2022

Stargardt Disease

Stargardt disease is a type of inherited age-related macular degeneration that causes vision loss in children or young adults.The retina contains light-sensing cells called photoreceptors, which include rods and cones. Rods are in the outer retina and help people when lighting is dim and dark. Cones are in the macula and help people see intricate visual detail and color. Both cones and rods negatively affected in Stargardt disease, cones are more strongly impacted in people who have Stargardt disease.

The Global Stargardt Disease Therapeutics Market is estimated to be valued at US$ 213.5 million in 2023 and is expected to exhibit a CAGR of 31.7% during the forecast period (2023 - 2028).

Retinitis Pigmentosa

Retinitis pigmentosa (RP) is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. People with RP experience a gradual decline in their vision, because photoreceptors degenerate. Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells.  Retinitis Pigmentosa (RP), an acquired retinal condition that causes retinal depletion, is an uncommon illness. Its underlying manifestations are decreased night vision along with loss of fringe vision. It slowly causes visual impairment. There is no conclusive remedy for retinitis pigmentosa. Hence medical institutions and various research and development centers are researching to develop a full proof cure for this disease which is boosting the growth of global retinitis pigmentosa market.

 Various studies suggest that this disease affects about 1 in 4,000 individuals worldwide. Without treatment, patients permanently lose central vision by the age of 60.

Choroideremia

Choroideremia is a hereditary degeneration of the retina in males that causes a gradual loss of vision. It starts in early childhood with night-blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. The lack of a functional protein in the retina causes cell death that is followed by the gradual deterioration of the retinal pigment epithelium, photoreceptors, and the choroid. Choroideremia results in progressive loss of vision and is more prominent in males. The first symptom of choroideremia is usually night blindness that occurs at an early stage.
Vision loss occurs due to degeneration of light-sensitive tissue cell. Nearly every patient with choroideremia develops progressive reduction of vision at a later stage.

As per Center for Disease Control and Prevention (CDC), 1 in 50,000-100,000 among U. S. population is suffering from choroideremia disease. The Choroideremia disease is a genetic, rare and degenerative disorder with lack of specific treatment and currently there is unmet demand of novel treatments in the choroideremia treatment market.

Global Choroideremia Treatment market is expected to account for $4.3 Billion by 2028 

Late Onset Retinal Degeneration

Late-onset retinal degeneration occurs in adulthood and is an inherited retinal dystrophy. It leads to central vision loss.

https://www.sciencedaily.com/releases/2021/12/211209133927.htm

Diabetic Retinopathy

Diabetic retinopathy is the leading cause of blindness in adults. It is a complication of diabetes that causes damage to the blood vessels of the retina. At first, diabetic retinopathy may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The global diabetic retinopathy market reached a value of US$ 7.64 Billion in 2020. and is expected to register a CAGR of 7.6% over the forecast period. Market growth can be primarily attributed to increased funding by regulatory bodies for researching ocular disorders.

The growing incidence of retinal disorders around the globe and the need for effective and affordable treatment options for the same has also driven the market. The National Eye Institute estimates that by 2030 and 2050, around 10 and 14 million people respectively will suffer from diabetic retinopathy in America.  The NCBI estimates that by 2040, individuals with early and late AMD will range between 14.9-21.5 million and 3.9-4.8 million respectively in Europe. The increasing geriatric population is also anticipated to be a major factor governing the overall market. According to data published in the World Population Prospects: 2019 Revision, around 1 in 11 and 1 in 4 people living in North America and Europe, respectively, will be aged 65 years and above by 2050.

REFERENCE LINK:  https://curativebiotech.com/pipeline

 

 
MANAGEMENT TEAM 
 
Paul M Michaels
Chairman and 
President
 
Barry A Ginsberg, O.D.
Chief Strategy Officer
 
I. Richard Garr, J.D.
CEO, General Counsel
 
Ronald W. Bordens, Ph.D.
EVP, Eng.& Ops.

SCIENTIFIC ADVISORY BOARD
 
Michael J. Grace, Ph.D
Chairman of Scientific Advisory Board
Has 30 years of executive and technical experience in both research and development of protein therapeutics and peptides within the biotechnology industry at Schering-Plough, Bristol Myers Squibb, NPS Pharma and Advaxis Inc. He has contributed to or personally led the development to commercial approval of 9 drugs by FDA and EMA including PEG-IntronTM, OrenciaTM, NulojixTM, YervoyTM, GattexTM and NatparaTM. His experience encompasses all aspects of drug development from discovery, process development, analytical development, quality control and regulatory affairs.
 
Kapil Bharti, Ph.D.
Advisor
From the National Eye Institute (NEI) at the National Institutes of Health (NIH) and is the lead inventor on the U.S. and Worldwide patent applications licensed exclusively to Curative Biotech to repurpose Metformin into an eye drop to treat degenerative eye diseases like macular degeneration, diabetic retinopathy, Stargardt’s disease, and others.
 
Dimiter S Dimitrov, Ph.D
Advisor

From 1990 to 2017, worked at National Cancer Insitute of the NIH. Since 2017 Director of  Center for Antibody Therapeutics at University of Pittsburgh. Dr. Dimitrov’s major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles, several books, and is the inventor or coinventor of more than 100 inventions, patent applications or patents. Dr. Dimitrov is the lead inventor on the Antibody Drug Conjugate patent exclusively licensed to Curative Biotech from the National Cancer Institute to treat glioblastoma.  

Nicholas Boullis, MD/Ph.D
Advisor
On the faculty of the Emory School of Medicine in Atlanta. Director of Emory University's Gene and Cell Therapy for Neurorestoration Laboratory. His research and clinical accomplishments include a path-breaking approach to spinal cord-delivered therapeutics and over 100 peer-reviewed publications in journals including Neurobiology Disease, Operative Neurosurgery, Clinical Neurology and Neurosurgery, Journal of Clinical Neuroscience, and Experimental Neurology, among others.

Catherine Sohn. Ph.D
Special Advisor to the Board of Director and CEO

Currently President of Sohn Health Strategies and Adjunct Professor at the University of California, San Francisco. 

Dr. Sohn has deep biopharmaceutical industry knowledge with over thirty (30) years of U.S. and global experience with expertise in the development and introduction of new medicines for patients and diseases with significant unmet needs. Her skill sets include strategic product development, business development and the introduction of new vaccines, pharmaceutical products and consumer healthcare brands.

Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Subsequently, she led the US commercialization of the company’s largest CNS product. Dr. Sohn later became senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions, including the $1.3 billion acquisition and integration of Block Drug and the $566 million acquisition of CNS, Inc.

 
 Curative Biotech OTC Profile:
https://www.otcmarkets.com/stock/CUBT/overview
 

Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-gen COVID-19 Vaccine

License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies

Boca Raton, FL, October 7, 2021 (GLOBE NEWSWIRE) — Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”) announced today that the Company has reached agreement with Mid-Atlantic BioTherapeutics (MABT) to broaden its previously announced license of IMT504, a novel patented immunotherapy and adjuvant, to include the development of a next generation COVID-19 vaccine. The Company will initially develop the vaccine to address the kidney failure patient population.  This new license, utilizing IMT504 as an adjuvant on top of a proprietary protein vaccine, adds a second infectious disease program to the Curative Biotech product development portfolio which also includes a reformulation of Metformin licensed from the National Eye Institute at National Institutes of Health (NIH) to treat degenerative eye diseases; and a novel monoclonal antibody/drug combination to treat brain cancer licensed from the National Cancer Institute at NIH.

“It is becoming increasingly clear that the initial COVID-19 vaccines developed are not working for everyone.  There are highly vulnerable people, such as those patients with kidney failure who require kidney transplantation or dialysis, who are being left behind.  We need targeted vaccines for this immunocompromised patient group,” said Curative Biotech Chairman & President Paul Michaels.

Curative Biotech and Mid-Atlantic BioTherapeutics have agreed to develop a next generation COVID-19 vaccine targeted to meet the needs of this vulnerable population.  A consequence of kidney failure in general is the loss of a robust immunologic response to infections, including COVID-19.  This means that kidney failure patients may get a more severe version of COVID-19 that could lead to a greater chance of hospitalization or even death.

Dr. David Horn, CEO of Mid-Atlantic BioTherapeutics, added: “It is well known that kidney transplant recipients have impaired responses to mRNA COVID-19 vaccines.  Recent data from France reveals that, even after 4 vaccine shots, many kidney transplant recipients have poor responses. In addition, kidney failure patients on dialysis do not initially respond as well to current vaccines and rapidly lose measurable antibodies when compared to the general population.”

As previously announced, Curative Biotech has acquired the worldwide rights for the development of IMT504 to treat symptomatic rabies.   Curative Biotech and MABT are already working together to develop IMT504 to treat patients whose disease has advanced to a stage where the virus has migrated to the brain, causing lethal rabies encephalitis. There are currently no treatment options for these patients. IMT504 has already been granted orphan drug designation in the US for the treatment of rabies, which may provide significant benefits including tax credits, market exclusivity and the waiver of certain FDA fees. Rabies is one of only a limited number of diseases which qualify for the FDA Tropical Disease Priority Review Voucher (PRV) Program that is granted to sponsors of approved tropical disease product applications that meet certain criteria. Once the sponsor obtains a PRV, the voucher can be used to obtain priority review designation for a subsequent application that does not itself qualify for priority review as described in the guidance, and it can be sold to another party.

Chairman Michaels concluded, “We are excited to begin work on this additional program and expect to announce additional important management resources at Curative Biotech to supplement the clinical development team.”

Future Curative Biotechnology Press Releases and Industry Updates

Interested investors and shareholders will receive press releases and industry updates by sending an e-mail to ir@curativebiotech.com.

About Mid-Atlantic BioTherapeutics, Inc. https://mabt.us/

Mid-Atlantic BioTherapeutics was founded in 2011 with the mission of eradicating infectious diseases. MABT is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of novel anti-infective approaches, such as the patented IMT504 immunotherapy platform, that harnesses the body’s own immune response to fight off infections. The company is actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for bacterial and viral diseases, emerging infectious diseases, and biodefense.

About Curative Biotechnology, Inc. http://curativebiotech.com

Curative Biotech is a development-stage biomedical company focusing on novel treatments for rare or currently unmet medical needs. Curative Biotech is focused on therapies with potentially accelerated development paths resulting from either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.) At Curative Biotech, we envision a world where all patients have a therapeutic option.

Contact:

Steve Chizzik
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com

LINK  https://www.biospace.com/article/releases/curative-biotechnology-announces-imt504-license-for-development-of-proprietary-next-gen-covid-19-vaccine/

Connectyx (now Curative Botechnology) Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease

Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD).

The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide.

The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.

Research has shown that Metformin, an FDA-approved drug that has been widely used for the treatment of diabetes in the United States since 1995, can activate AMP-activated protein kinase, can reduce vascular endothelial growth factor (VEGF) secretion, and can correct baseline calcium levels in patient RPE cells. The new treatment indications will require reformulating the drug into an eye drop, injectable or other topical delivery method to be able to deliver sufficient drug to the RPE layer to have a therapeutic effect. This reformulated drug should be eligible for a 505(b)(2) accelerated development path. While the field of use covers treating any degenerative eye disease, the Company is targeting Stargardt, a currently untreatable orphan disease that causes vision loss in children, as the first indication for this therapeutic product.

Paul Michaels, Chairman and President of Connectyx, said, “We are pleased to expand our product portfolio with the addition of reformulated and repurposed Metformin, which is the fifth most prescribed drug in the United States. This very promising product adds a second in licensed product from the NIH to our development portfolio. As stated above, we believe our Metformin reformulation may show efficacy in treating a wide range of RD diseases that cause vision loss. We are focused on developing disease modifying therapeutics to meet the unmet needs of patients. The Company anticipates being prepared for human testing of this reformulation by third quarter of 2022.”

About Age-Related Macular Degeneration, Stargardt Disease, Retinitis Pigmentosa and Choroideremia

AMD is the leading cause of vision loss in people ages 60+. It destroys a patient’s sharp, central vision. Stargardt disease is a type of AMD that causes vision loss in children or young adults. Retinitis pigmentosa is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. Choroideremia is a hereditary retinal degeneration that causes a gradual loss of vision. It starts in early childhood with night blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. Diabetic retinopathy is the leading cause of blindness in adults. Diabetes harms blood vessels inside the eye by weakening them so they leak fluid into the retina, which can damage areas of the retina, causing blurry, distorted vision.

About Mid-Atlantic BioTherapeutics

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called “immunotherapy”. Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications. Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity.  

CUBT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#37692  Sticky Note It is a toxic note with $142K taken trader59 03/10/22 12:42:55 PM
#30408  Sticky Note CTYX DD Packet with hyper links! http://tinyurl.com/curativebiodd Connectyx ( Eagle1 02/06/21 05:30:12 PM
#29144  Sticky Note This turd does not have the right to pepeoil 12/07/20 07:45:36 AM
#28773  Sticky Note DD on why this is not a game: https://investorshub.advfn.com/boards/read_ RiseandShine 10/31/20 09:31:59 PM
#38568   The Green Gecko!!! sctts 05/18/22 05:25:51 PM
#38566   I do not think that an office is lizardlover 05/18/22 10:29:41 AM
#38565   No office, no hope. Lol. pepeoil 05/18/22 05:23:07 AM
#38564   No you don't understand. lizardlover 05/17/22 04:12:16 PM
#38563   Buy the bid. Sell the ask. govprs 05/17/22 03:55:45 PM
#38561   Notice the HUGE spread. lizardlover 05/17/22 12:37:08 PM
#38560   BINGO ! lizardlover 05/17/22 10:38:32 AM
#38559   Another downer. That’s too bed. baberuth1974 05/17/22 05:49:22 AM
#38558   Yes, 99% of these stinky pinky scams are pepeoil 05/17/22 01:10:12 AM
#38556   Someone is buying these beautiful sloppy seconds. baberuth1974 05/16/22 09:59:51 PM
#38555   Those damn evil shorts man ! lizardlover 05/16/22 07:47:12 PM
#38554   I agree adding here is a good idea Hawkeiz 05/16/22 07:11:40 PM
#38552   All good. Respect your opinion. Threeflight 05/16/22 06:13:14 PM
#38551   I do. You will see soon enough doubting Thomas. baberuth1974 05/16/22 05:43:56 PM
#38549   Surprisingly for drug development CUBT is moving pretty steady. Gonzal 05/16/22 05:16:04 PM
#38548   Sure we don't ! lizardlover 05/16/22 04:54:52 PM
#38547   All the posters on this board have absolutely baberuth1974 05/16/22 04:51:09 PM
#38546   Like asking the scorpion crossing the river sctts 05/16/22 01:10:58 PM
#38545   NIH this NIH that..... lizardlover 05/16/22 01:09:23 PM
#38544   Push that price down...to take a position. conix 05/16/22 01:04:41 PM
#38543   I know u lost out your investment here, pacman181 05/16/22 11:36:30 AM
#38542   NO NO NO and just NO. lizardlover 05/16/22 10:57:39 AM
#38541   The hope is that the low volume move tdgnts 05/16/22 08:42:58 AM
#38539   Why would they give investors anything? pepeoil 05/16/22 07:31:40 AM
#38538   No idea on each other than I would Threeflight 05/16/22 02:45:51 AM
#38537   Non dilutive? Not so sure about that. What Wrangler1 05/15/22 11:02:16 PM
#38536   This company is worth more than its current Threeflight 05/15/22 07:24:45 PM
#38535   Ocular drug delivery is a HUGE category!! Student of the Game 05/15/22 12:05:36 PM
#38534   NIce CUBT adds Conix, we know this can Eagle1 05/13/22 08:48:02 PM
#38532   You have been busy lately sctts 05/13/22 06:48:29 PM
#38531   https://finance.yahoo.com/news/extensive-pharmaceutical-research-open-floodgates Wrangler1 05/13/22 06:26:11 PM
#38530   Very happy to participate today. conix 05/13/22 05:50:31 PM
#38529   You know that bulls are getting extremely desperate lizardlover 05/13/22 05:06:09 PM
#38528   Recovery? 38 trades all day long with trader59 05/13/22 04:43:03 PM
#38527   Nice little recovery today. tdgnts 05/13/22 04:09:39 PM
#38526   Yeah that ain’t no shit iRobot 05/12/22 09:23:37 PM
#38525   My focus is what he will do for sctts 05/12/22 08:00:41 PM
#38524   Wonder how many shares they’ll gift this newest Report the Vio 05/12/22 05:52:09 PM
#38523   LOL good one. Threeflight 05/12/22 04:33:09 PM
#38522   Curative Biotechnology, Inc. Names Cary Sucoff to Board conix 05/12/22 02:38:51 PM
#38521   sure hope so these prices are crap i_like_bb_stock 05/12/22 01:50:17 PM
#38520   They might be successful or they might not. lizardlover 05/12/22 01:13:46 PM
#38519   Yes tough name for sure! Guess at the kingoraschmuck 05/12/22 12:38:23 PM
#38518   Dude give it a rest yes I think iRobot 05/12/22 12:32:07 PM
#38517   yes cary sucoff how could u go through i_like_bb_stock 05/12/22 12:22:00 PM
#38516   GREAT JOB CUBT. lizardlover 05/12/22 12:20:53 PM
#38515   Finally you understand :) lizardlover 05/12/22 12:19:45 PM
#38514   What are you referring to?? Did we get iRobot 05/12/22 12:09:13 PM
#38513   New board member Sucoff that sounds about right i_like_bb_stock 05/12/22 11:54:03 AM
#38512   No I’m good I learned my lesson nobody iRobot 05/12/22 11:50:25 AM
PostSubject
Consent Preferences